Detalhe da pesquisa
1.
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Nature;
602(7898): 682-688, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35016197
2.
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
Sci Transl Med;
15(683): eabo2847, 2023 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36791207
3.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
NPJ Vaccines;
8(1): 67, 2023 May 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37164959
4.
An In Vitro Microneutralization Assay for Influenza Virus Serology.
Curr Protoc;
2(7): e465, 2022 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35848945
5.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
medRxiv;
2022 Feb 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35169806
6.
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
Front Immunol;
12: 791764, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34868082
7.
Correction: An In Vitro Microneutralization Assay for Influenza Virus Serology.
Curr Protoc;
2(9): e567, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36066324